ALTERITY THERAPEUTICS LTD
ATHEDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 27, 2026
6wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ATH434 dose level 1 | Phase 2 | Multiple System Atrophy | - | - |
ATH434 | Phase 2 | Multiple System Atrophy | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in ALTERITY THERAPEUTICS LTD's drug pipeline?→
CatalystAlert tracks 2 drug candidates in ALTERITY THERAPEUTICS LTD's (ATHE) pipeline across Phase 2. Its lead program is ATH434 dose level 1 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ALTERITY THERAPEUTICS LTD's next FDA catalyst?→
ALTERITY THERAPEUTICS LTD's (ATHE) next tracked catalyst is a Earnings expected August 27, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ATHE biotech catalysts?→
Add ATHE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ALTERITY THERAPEUTICS LTD's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.